PA8474101A1
(es)
|
1998-06-19 |
2000-09-29 |
Pfizer Prod Inc |
Compuestos de pirrolo [2,3-d] pirimidina
|
TR200003719T2
(tr)
*
|
1998-06-19 |
2001-03-21 |
Pfizer Products Inc. |
Pirolo[2,3-d]Pirimidin bileşikleri
|
PL218519B1
(pl)
|
1999-12-10 |
2014-12-31 |
Pfizer Prod Inc |
Związki pirolo [2,3-d] pirymidynowe, środek farmaceutyczny zawierający te związki oraz ich zastosowanie
|
ITMI992711A1
(it)
*
|
1999-12-27 |
2001-06-27 |
Novartis Ag |
Composti organici
|
YU83302A
(sh)
*
|
2000-06-26 |
2005-09-19 |
Pfizer Products Inc. |
Jedinjenja pirolo (2,3-d) pirimidina kao imunosupresivni agensi
|
US7301023B2
(en)
*
|
2001-05-31 |
2007-11-27 |
Pfizer Inc. |
Chiral salt resolution
|
GB0115393D0
(en)
*
|
2001-06-23 |
2001-08-15 |
Aventis Pharma Ltd |
Chemical compounds
|
KR100875380B1
(ko)
*
|
2001-06-23 |
2008-12-23 |
아벤티스 파마슈티칼스 인크. |
단백질 키나제 억제제로서의 피롤로피리미딘
|
GB0121033D0
(en)
*
|
2001-08-30 |
2001-10-24 |
Novartis Ag |
Organic compounds
|
GT200200234A
(es)
*
|
2001-12-06 |
2003-06-27 |
|
Compuestos cristalinos novedosos
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
MXPA05001096A
(es)
|
2002-07-29 |
2005-11-23 |
Rigel Pharmaceuticals Inc |
Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
|
EP1388541A1
(en)
|
2002-08-09 |
2004-02-11 |
Centre National De La Recherche Scientifique (Cnrs) |
Pyrrolopyrazines as kinase inhibitors
|
BR0316470A
(pt)
*
|
2002-11-21 |
2005-10-11 |
Pfizer Prod Inc |
Derivados de 3-amino-piperadina e métodos de preparação
|
EP1572213A1
(en)
|
2002-11-26 |
2005-09-14 |
Pfizer Products Inc. |
Method of treatment of transplant rejection
|
CA2753318A1
(en)
|
2003-05-30 |
2004-12-09 |
Ranbaxy Laboratories Limited |
Substituted pyrrole derivatives
|
US8178671B2
(en)
|
2003-07-30 |
2012-05-15 |
Rigel Pharmaceuticals, Inc. |
Methods of treating or preventing autoimmune diseases with 2, 4-pyrimidinediamine compounds
|
CA2545192A1
(en)
*
|
2003-11-25 |
2005-06-09 |
Pfizer Products Inc. |
Method of treatment of atherosclerosis
|
US20050137679A1
(en)
*
|
2003-12-17 |
2005-06-23 |
Pfizer Inc |
Modified stent useful for delivery of drugs along stent strut
|
CN1893952A
(zh)
*
|
2003-12-17 |
2007-01-10 |
辉瑞产品公司 |
用于治疗移植排斥的吡咯并[2,3-d]嘧啶化合物
|
WO2005063251A1
(en)
*
|
2003-12-17 |
2005-07-14 |
Pfizer Products Inc. |
Modified stent useful for delivery of drugs along stent strut
|
US20050153990A1
(en)
*
|
2003-12-22 |
2005-07-14 |
Watkins William J. |
Phosphonate substituted kinase inhibitors
|
US20070281907A1
(en)
*
|
2003-12-22 |
2007-12-06 |
Watkins William J |
Kinase Inhibitor Phosphonate Conjugates
|
WO2005069865A2
(en)
*
|
2004-01-13 |
2005-08-04 |
Ambit Biosciences Corporation |
Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
|
HUP0400891A2
(en)
*
|
2004-04-29 |
2006-04-28 |
Janos Szolcsanyi |
7h-pyrrolo[2,3-d]pyrimidine derivatives, their pharmaceutically acceptable salts, pharmaceutical compositions containing them and process for the production of the compounds
|
EP1755680A1
(en)
*
|
2004-05-03 |
2007-02-28 |
Novartis AG |
Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor
|
MXPA06015237A
(es)
*
|
2004-06-29 |
2007-12-10 |
Amgen Inc |
Pirrolo[2-3-d]pirimidinas que modulan la actividad de ack1 y lck.
|
JP2008520612A
(ja)
*
|
2004-11-24 |
2008-06-19 |
ノバルティス アクチエンゲゼルシャフト |
JAK阻害剤およびBcr−Abl、Flt−3、FAKまたはRAFキナーゼ阻害剤のうち少なくとも1個の組合せ
|
AR054416A1
(es)
*
|
2004-12-22 |
2007-06-27 |
Incyte Corp |
Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas.
|
CN101142218B
(zh)
|
2005-02-03 |
2013-02-06 |
沃泰克斯药物股份有限公司 |
可用作蛋白激酶抑制剂的吡咯并嘧啶
|
WO2006091450A1
(en)
*
|
2005-02-18 |
2006-08-31 |
Lexicon Genetics Incorporated |
4-piperidin-1-yl-7h-pyrrolo[2,3-d]pyrimidine compounds
|
RU2411242C2
(ru)
|
2005-05-13 |
2011-02-10 |
Айрм, Ллк. |
Соединения и композиции в качестве ингибиторов протеинкиназ
|
EP1904457B1
(en)
|
2005-06-08 |
2017-09-06 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
CN102127078A
(zh)
|
2005-07-14 |
2011-07-20 |
安斯泰来制药株式会社 |
Janus激酶3的杂环类抑制剂
|
KR20080026654A
(ko)
|
2005-07-14 |
2008-03-25 |
아스텔라스세이야쿠 가부시키가이샤 |
헤테로시클릭 야누스 키나제 3 억제제
|
AU2006273762A1
(en)
|
2005-07-29 |
2007-02-01 |
Pfizer Products Inc. |
Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis
|
EP2270014A1
(en)
|
2005-09-22 |
2011-01-05 |
Incyte Corporation |
Azepine inhibitors of janus kinases
|
US8026377B2
(en)
|
2005-11-08 |
2011-09-27 |
Ranbaxy Laboratories, Limited |
Process for (3R, 5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-[(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid hemi calcium salt
|
LT2474545T
(lt)
|
2005-12-13 |
2017-02-27 |
Incyte Holdings Corporation |
Heteroarilu pakeisti pirolo[2,3-b]piridinai ir pirolo[2,3-b]pirimidinai kaip janus kinazės inhibitoriai
|
US8962643B2
(en)
|
2006-02-24 |
2015-02-24 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the JAK pathway
|
GB0605691D0
(en)
*
|
2006-03-21 |
2006-05-03 |
Novartis Ag |
Organic Compounds
|
SG170828A1
(en)
*
|
2006-04-05 |
2011-05-30 |
Vertex Pharmaceuticals Inc Us |
Deazapurines useful as inhibitors of janus kinases
|
WO2008029237A2
(en)
*
|
2006-09-05 |
2008-03-13 |
Pfizer Products Inc. |
Combination therapies for rheumatoid arthritis
|
WO2008033745A2
(en)
*
|
2006-09-11 |
2008-03-20 |
Curis, Inc. |
Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
|
US20080221132A1
(en)
*
|
2006-09-11 |
2008-09-11 |
Xiong Cai |
Multi-Functional Small Molecules as Anti-Proliferative Agents
|
EP1900729A1
(en)
*
|
2006-09-15 |
2008-03-19 |
Novartis AG |
Benzoxazoles and oxazolopyridines being useful as Janus kinases inhibitors
|
ES2415863T3
(es)
|
2006-12-22 |
2013-07-29 |
Incyte Corporation |
Heterociclos sustituidos como inhibidores de Janus Quinasas
|
KR20090106604A
(ko)
|
2007-01-12 |
2009-10-09 |
아스텔라스세이야쿠 가부시키가이샤 |
축합 피리딘 화합물
|
LT3070090T
(lt)
|
2007-06-13 |
2019-06-25 |
Incyte Holdings Corporation |
Janus kinazės inhibitoriaus (r)-3-(4-(7h-pirol[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)-3-ciklopentilpropannitrilo druskų panaudojimas
|
CL2008001709A1
(es)
*
|
2007-06-13 |
2008-11-03 |
Incyte Corp |
Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
|
KR20120115413A
(ko)
|
2007-07-11 |
2012-10-17 |
화이자 인코포레이티드 |
안구 건조증 치료용 약학 조성물 및 방법
|
WO2009055674A1
(en)
*
|
2007-10-26 |
2009-04-30 |
Targegen Inc. |
Pyrrolopyrimidine alkynyl compounds and methods of making and using same
|
US8309718B2
(en)
|
2007-11-16 |
2012-11-13 |
Incyte Corporation |
4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors
|
NZ587271A
(en)
|
2008-02-06 |
2012-03-30 |
Novartis Ag |
Pyrrolo[2,3-d]pyrimidines containing a 7h-pyrrolo[2,3-d]pyrimidin-2-yl core and use thereof as tyrosine kinase inhibitors
|
CA2715658C
(en)
|
2008-02-15 |
2016-07-19 |
Rigel Pharmaceuticals, Inc. |
Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
|
DK2288610T3
(en)
|
2008-03-11 |
2016-11-28 |
Incyte Holdings Corp |
Azetidinesulfonic AND CYCLOBUTANDERIVATER AS JAK INHIBITORS
|
US8138339B2
(en)
|
2008-04-16 |
2012-03-20 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
BRPI0910921B1
(pt)
|
2008-04-16 |
2022-06-21 |
Portola Pharmaceuticals, Inc |
Inibidores de proteína syk quinase, composição farmacêutica, kit e usos dos referidos inibidores
|
JP2011518219A
(ja)
|
2008-04-22 |
2011-06-23 |
ポートラ ファーマシューティカルズ, インコーポレイテッド |
タンパク質キナーゼの阻害剤
|
EP2274288A2
(en)
|
2008-04-24 |
2011-01-19 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
CA2732628A1
(en)
*
|
2008-08-01 |
2010-02-04 |
Biocryst Pharmaceuticals, Inc. |
Therapeutic agents
|
PT2384326E
(pt)
|
2008-08-20 |
2014-06-09 |
Zoetis Llc |
Compostos de pirrolo[2,3-d]pirimidina
|
US8385364B2
(en)
*
|
2008-09-24 |
2013-02-26 |
Nec Laboratories America, Inc. |
Distributed message-passing based resource allocation in wireless systems
|
EP2348860B1
(en)
|
2008-10-31 |
2015-05-27 |
Genentech, Inc. |
Pyrazolopyrimidine jak inhibitor compounds and methods
|
DE102008063597A1
(de)
|
2008-12-18 |
2010-07-01 |
Schaeffler Technologies Gmbh & Co. Kg |
Dichtungsanordnung mit Dichtlippenschutz
|
JOP20190230A1
(ar)
|
2009-01-15 |
2017-06-16 |
Incyte Corp |
طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
|
WO2010085597A1
(en)
|
2009-01-23 |
2010-07-29 |
Incyte Corporation |
Macrocyclic compounds and their use as kinase inhibitors
|
EP2396004A4
(en)
|
2009-02-11 |
2012-07-25 |
Reaction Biology Corp |
SELECTIVE KINASE HEMMER
|
CA2758614A1
(en)
|
2009-04-14 |
2010-10-21 |
Cellzome Limited |
Fluoro substituted pyrimidine compounds as jak3 inhibitors
|
JP5709276B2
(ja)
*
|
2009-04-20 |
2015-04-30 |
オースペックス ファーマシューティカルズ,エルエルシー |
ヤヌスキナーゼ3のピペリジンインヒビター
|
JP5775070B2
(ja)
|
2009-05-22 |
2015-09-09 |
インサイト・コーポレイションIncyte Corporation |
ヤヌスキナーゼ阻害剤としてのピラゾール−4−イル−ピロロ[2,3−d]ピリミジンおよびピロール−3−イル−ピロロ[2,3−d]ピリミジンのN−(ヘテロ)アリール−ピロリジン誘導体
|
MY161416A
(en)
|
2009-05-22 |
2017-04-14 |
Incyte Holdings Corp |
3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4yl)-1h-pyrazol-1-yl]octane-or heptane-nitrile as jak inhibitors
|
UA110324C2
(xx)
*
|
2009-07-02 |
2015-12-25 |
Genentech Inc |
Інгібуючі jak сполуки на основі піразолопіримідину
|
US9346809B2
(en)
|
2009-07-08 |
2016-05-24 |
Leo Pharma A/S |
Heterocyclic compounds as JAK receptor and protein tyrosine kinase inhibitors
|
TWI466885B
(zh)
*
|
2009-07-31 |
2015-01-01 |
Japan Tobacco Inc |
含氮螺環化合物及其醫藥用途
|
US9249145B2
(en)
|
2009-09-01 |
2016-02-02 |
Incyte Holdings Corporation |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
US20120172385A1
(en)
|
2009-09-11 |
2012-07-05 |
Richard John Harrison |
Ortho substituted pyrimidine compounds as jak inhibitors
|
WO2011044481A1
(en)
*
|
2009-10-09 |
2011-04-14 |
Incyte Corporation |
Hydroxyl, keto, and glucuronide derivatives of 3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
|
JP5629324B2
(ja)
|
2009-10-15 |
2014-11-19 |
ファイザー・インク |
ピロロ[2,3−d]ピリミジン化合物
|
AU2010309882B2
(en)
|
2009-10-20 |
2016-01-28 |
Cellzome Limited |
Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors
|
JP5739446B2
(ja)
|
2009-12-18 |
2015-06-24 |
ファイザー・インク |
ピロロ[2,3−d]ピリミジン化合物
|
BR112012017269A2
(pt)
*
|
2010-01-12 |
2016-05-03 |
Hoffmann La Roche |
compostos heterocíclicos tricíclicos, composições e métodos de uso dos mesmos
|
US20120309776A1
(en)
|
2010-02-05 |
2012-12-06 |
Pfitzer Inc. |
Pyrrolo[2,3-d]pyrimidine urea compounds as jak inhibitors
|
AR081315A1
(es)
|
2010-03-10 |
2012-08-08 |
Incyte Corp |
Derivados heterociclicos de piperidin y pirimidin -4-il-azetidina, una forma cristalina de la sal del acido acetonitriladipico de un derivado pirimidinico, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades relacionadas con la inhibicion de jak-1, t
|
BR112012027803A2
(pt)
|
2010-04-30 |
2016-08-09 |
Cellzome Ltd |
compostos de pirazol como inibidores de jak
|
ME02445B
(me)
|
2010-05-21 |
2016-09-20 |
Incyte Holdings Corp |
Topikalna formulacija za inhibiciju jak-a
|
WO2011149827A1
(en)
*
|
2010-05-24 |
2011-12-01 |
Glaxosmithkline Llc |
Compounds and methods
|
CN101851241B
(zh)
*
|
2010-07-02 |
2012-05-23 |
西安交通大学 |
一种抗肿瘤化合物及其制备方法和其用途
|
US9040545B2
(en)
|
2010-08-20 |
2015-05-26 |
Cellzome Limited |
Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors
|
EP2635557A2
(en)
|
2010-11-01 |
2013-09-11 |
Portola Pharmaceuticals, Inc. |
Nicotinamides as jak kinase modulators
|
US9034884B2
(en)
|
2010-11-19 |
2015-05-19 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
|
AR083933A1
(es)
|
2010-11-19 |
2013-04-10 |
Incyte Corp |
Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
|
EP2661436B1
(en)
*
|
2011-01-07 |
2016-04-13 |
Leo Pharma A/S |
Novel sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
|
EP2675451B9
(en)
|
2011-02-18 |
2017-07-26 |
Novartis Pharma AG |
mTOR/JAK INHIBITOR COMBINATION THERAPY
|
WO2012127506A1
(en)
|
2011-03-22 |
2012-09-27 |
Advinus Therapeutics Limited |
Substituted fused tricyclic compounds, compositions and medicinal applications thereof
|
EP2691395B1
(en)
|
2011-03-28 |
2017-08-30 |
ratiopharm GmbH |
Processes for preparing tofacitinib salts
|
US9050342B2
(en)
|
2011-03-29 |
2015-06-09 |
Pfizer Inc. |
Beneficial effects of combination therapy on cholesterol
|
WO2012137111A1
(en)
*
|
2011-04-08 |
2012-10-11 |
Pfizer Inc. |
Crystalline and non- crystalline forms of tofacitinib, and a pharmaceutical composition comprising tofacitinib and a penetration enhancer
|
WO2012143320A1
(en)
|
2011-04-18 |
2012-10-26 |
Cellzome Limited |
(7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
|
PE20140832A1
(es)
|
2011-06-20 |
2014-07-14 |
Incyte Corp |
Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
|
AU2012288892B2
(en)
|
2011-07-28 |
2016-04-21 |
Cellzome Limited |
Heterocyclyl pyrimidine analogues as JAK inhibitors
|
WO2013017480A1
(en)
|
2011-07-29 |
2013-02-07 |
Cellzome Limited |
Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
|
WO2013017479A1
(en)
|
2011-07-29 |
2013-02-07 |
Cellzome Limited |
Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
|
JP2014521725A
(ja)
|
2011-08-10 |
2014-08-28 |
ノバルティス・ファルマ・アクチェンゲゼルシャフト |
JAKPI3K/mTOR併用療法
|
EP2742049A1
(en)
*
|
2011-08-12 |
2014-06-18 |
Nissan Chemical Industries, Ltd. |
Tricyclic heterocyclic compounds and jak inhibitors
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為jak抑制劑之環己基氮雜環丁烷衍生物
|
GB2494173A
(en)
*
|
2011-09-01 |
2013-03-06 |
Vectair Systems Ltd |
Dispensing apparatus
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
RU2014115476A
(ru)
|
2011-09-20 |
2015-10-27 |
Целльзом Лимитед |
Производные пиразоло[4, 3-с]птридина в качестве ингибиторов киназ
|
CA2856301C
(en)
|
2011-11-23 |
2020-10-06 |
Portola Pharmaceuticals, Inc. |
Pyrazine kinase inhibitors
|
CN104185420B
(zh)
|
2011-11-30 |
2017-06-09 |
埃默里大学 |
用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂
|
US8993756B2
(en)
*
|
2011-12-06 |
2015-03-31 |
Merck Sharp & Dohme Corp. |
Pyrrolopyrimidines as janus kinase inhibitors
|
WO2013090490A1
(en)
|
2011-12-15 |
2013-06-20 |
Ratiopharm Gmbh |
Tofacitinib salts
|
BR112014014325B1
(pt)
|
2011-12-21 |
2022-06-07 |
Jiangsu Hengrui Medicine Co.,Ltd. |
Derivados de pirrol do tipo anel heteroarílico de seis membros, seus usos e seus processos de preparação, e composição farmacêutica
|
RU2014130214A
(ru)
|
2011-12-23 |
2016-02-10 |
Целльзом Лимитид |
Пиримидин-2, 4-диаминовые производные в качестве ингибиторов киназы
|
WO2013173506A2
(en)
|
2012-05-16 |
2013-11-21 |
Rigel Pharmaceuticals, Inc. |
Method of treating muscular degradation
|
US9193733B2
(en)
|
2012-05-18 |
2015-11-24 |
Incyte Holdings Corporation |
Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
|
EP2903970A4
(en)
|
2012-10-08 |
2016-11-30 |
Portola Pharm Inc |
SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS
|
CN102936251A
(zh)
*
|
2012-11-05 |
2013-02-20 |
上海毕得医药科技有限公司 |
一种吡咯并[2,3-d]嘧啶衍生物的制备方法
|
CA3178452A1
(en)
|
2012-11-15 |
2014-05-22 |
Incyte Holdings Corporation |
Sustained-release dosage forms of ruxolitinib
|
US9481679B2
(en)
|
2012-12-17 |
2016-11-01 |
Sun Pharmaceutical Industries Limited |
Process for the preparation of tofacitinib and intermediates thereof
|
CN103896826B
(zh)
*
|
2012-12-26 |
2016-08-03 |
上海朴颐化学科技有限公司 |
氮保护的(3r,4r)-3-甲氨基-4-甲基哌啶的不对称合成方法、相关中间体及原料制备方法
|
ES2755130T3
(es)
|
2013-02-08 |
2020-04-21 |
Nissan Chemical Corp |
Compuesto de pirrolopiridina tricíclico, e inhibidor de JAK
|
JP6145179B2
(ja)
|
2013-02-22 |
2017-06-07 |
ファイザー・インク |
ヤヌス関連キナーゼ(JAK)の阻害剤としてのピロロ[2,3−d]ピリミジン誘導体
|
LT3489239T
(lt)
|
2013-03-06 |
2022-03-10 |
Incyte Holdings Corporation |
Jak inhibitoriaus gamybos būdai ir tarpiniai junginiai
|
JP6041823B2
(ja)
|
2013-03-16 |
2016-12-14 |
ファイザー・インク |
トファシチニブの経口持続放出剤形
|
US20140343034A1
(en)
*
|
2013-04-25 |
2014-11-20 |
Japan Tobacco Inc. |
Skin barrier function improving agent
|
US20160122354A1
(en)
*
|
2013-06-05 |
2016-05-05 |
Srinivasan Thirumalai Rajan |
PROCESS FOR THE PREPARATION OF (3R,4R)-4-METHYL-3-(METHYL-7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL-AMINO)-ß-OXO-1-PIPERIDINEPROPANENITRILE AND ITS SALTS
|
MY195091A
(en)
|
2013-08-07 |
2023-01-10 |
Incyte Corp |
Sustained Release Dosage Forms for a JAK1 Inhibitor
|
CN103819474A
(zh)
*
|
2013-11-04 |
2014-05-28 |
湖南华腾制药有限公司 |
一种托法替尼的制备方法
|
WO2015078417A1
(zh)
*
|
2013-11-29 |
2015-06-04 |
四川好医生药业集团有限公司 |
吡咯并嘧啶化合物及其在制备降血糖药物中的用途
|
JP6192839B2
(ja)
|
2013-12-05 |
2017-09-06 |
ファイザー・インク |
ピロロ[2,3−d]ピリミジニル、ピロロ[2,3−b]ピラジニル、およびピロロ[2,3−d]ピリジニルアクリルアミド
|
PL2994454T3
(pl)
|
2013-12-09 |
2019-09-30 |
Unichem Laboratories Limited |
Ulepszony sposób wytwarzania (3R,4R)-(1-benzylo-4-metylopiperydyn-3-ylo)metyloaminy
|
US9260438B2
(en)
|
2014-02-06 |
2016-02-16 |
Apotex Inc. |
Solid forms of tofacitinib salts
|
AU2015222865B2
(en)
|
2014-02-28 |
2019-06-20 |
Takeda Pharmaceutical Company Limited |
TYK2 inhibitors and uses thereof
|
US9890165B2
(en)
|
2014-05-14 |
2018-02-13 |
Nissan Chemical Industries, Ltd. |
Tricyclic compound and JAK inhibitor
|
CA2948589A1
(en)
|
2014-05-23 |
2015-11-26 |
F. Hoffmann-La Roche Ag |
5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are jak inhibitors
|
WO2015184305A1
(en)
|
2014-05-30 |
2015-12-03 |
Incyte Corporation |
TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1
|
JP6585158B2
(ja)
|
2014-08-12 |
2019-10-02 |
ファイザー・インク |
ヤヌスキナーゼの阻害に有用なピロロ[2,3−d]ピリミジン誘導体
|
JP6749890B2
(ja)
|
2014-08-12 |
2020-09-02 |
モナッシュ ユニバーシティ |
リンパ指向プロドラッグ
|
KR101710127B1
(ko)
|
2014-08-29 |
2017-02-27 |
한화제약주식회사 |
야누스인산화효소 억제제로서의 치환된 N-(피롤리딘-3-일)-7H-피롤로[2,3-d]피리미딘-4-아민
|
TWI744225B
(zh)
|
2015-02-27 |
2021-11-01 |
美商林伯士拉克許米公司 |
酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途
|
CN104761556B
(zh)
*
|
2015-03-21 |
2017-06-23 |
河北国龙制药有限公司 |
托法替布中间体杂质、托法替布杂质及其合成方法,以及托法替布的质量监控方法
|
EP3078665A1
(en)
|
2015-04-10 |
2016-10-12 |
OLON S.p.A. |
Efficient method for the preparation of tofacitinib citrate
|
ES2928757T3
(es)
|
2015-05-01 |
2022-11-22 |
Pfizer |
Acrilamidas de pirrolo[2,3-b]pirazinilo y epóxidos de las mismas como inhibidores de la Janus Quinasa
|
MX2017013797A
(es)
*
|
2015-05-29 |
2018-03-21 |
Wuxi Fortune Pharmaceutical Co Ltd |
Inhibidor de janus quinasa.
|
WO2017004134A1
(en)
|
2015-06-29 |
2017-01-05 |
Nimbus Iris, Inc. |
Irak inhibitors and uses thereof
|
KR101771219B1
(ko)
*
|
2015-08-21 |
2017-09-05 |
양지화학 주식회사 |
야누스 키나제 1 선택적 억제제 및 그 의약 용도
|
TWI707852B
(zh)
|
2015-09-02 |
2020-10-21 |
美商林伯士拉克許米公司 |
Tyk2 抑制劑及其用途
|
US11738087B2
(en)
|
2015-09-08 |
2023-08-29 |
Monash University |
Lymph directing prodrugs
|
WO2017044720A1
(en)
|
2015-09-11 |
2017-03-16 |
Navitor Pharmaceuticals, Inc. |
Rapamycin analogs and uses thereof
|
KR20180072704A
(ko)
|
2015-10-23 |
2018-06-29 |
나비토르 파마슈티칼스 인코포레이티드 |
세스트린-gator2 상호작용의 조절제 및 이의 용도
|
US10045981B2
(en)
|
2015-11-24 |
2018-08-14 |
Jakpharm, Llc |
Selective kinase inhibitors
|
TWI703147B
(zh)
|
2015-11-24 |
2020-09-01 |
美商施萬生物製藥研發Ip有限責任公司 |
用於治療胃腸發炎性疾病之jak抑制劑化合物之前藥
|
CN106831779B
(zh)
*
|
2015-11-28 |
2019-07-19 |
南昌弘益药业有限公司 |
一类jak激酶抑制剂的新化合物
|
CN105348287A
(zh)
*
|
2015-11-30 |
2016-02-24 |
宁波立华制药有限公司 |
一种枸橼酸托法替布的新型合成工艺
|
US20190083609A1
(en)
|
2016-01-18 |
2019-03-21 |
Helmoltz Zentrum München - Deutsches Forschungszentrum Für Gesundheit And Umwelt (Gmbh) |
Tofacitinib as vaccination immune modulator
|
WO2017156165A1
(en)
|
2016-03-09 |
2017-09-14 |
Raze Therapeutics, Inc. |
3-phosphoglycerate dehydrogenase inhibitors and uses thereof
|
PL3426244T3
(pl)
|
2016-03-09 |
2023-09-25 |
Raze Therapeutics, Inc. |
Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania
|
CN107513067A
(zh)
|
2016-06-16 |
2017-12-26 |
北京赛林泰医药技术有限公司 |
含有取代环戊基的吡咯并嘧啶化合物
|
CN109562106B
(zh)
|
2016-06-21 |
2023-03-21 |
X4 制药有限公司 |
Cxcr4抑制剂及其用途
|
CA3039202A1
(en)
|
2016-10-14 |
2018-04-19 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
AU2017345736B2
(en)
|
2016-10-21 |
2022-04-07 |
Takeda Pharmaceutical Company Limited |
TYK2 inhibitors and uses thereof
|
US10414727B2
(en)
|
2016-11-08 |
2019-09-17 |
Navitor Pharmaceuticals, Inc. |
Phenyl amino piperidine mTORC inhibitors and uses thereof
|
EP3543241B8
(en)
*
|
2016-11-23 |
2022-10-12 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Preparation method for and intermediate of pyrrolo six-membered heteroaromatic ring derivative
|
HUE055530T2
(hu)
*
|
2016-11-23 |
2021-12-28 |
Wuxi Fortune Pharmaceutical Co Ltd |
7H-pirrolo[2,3-D]pirimidin vegyület kristály formája és só formája, és ezek elkészítési eljárása
|
US11091451B2
(en)
|
2016-12-05 |
2021-08-17 |
Raze Therapeutics, Inc. |
SHMT inhibitors and uses thereof
|
US11730819B2
(en)
|
2016-12-23 |
2023-08-22 |
Bicycletx Limited |
Peptide derivatives having novel linkage structures
|
WO2018127699A1
(en)
|
2017-01-06 |
2018-07-12 |
Bicyclerd Limited |
Compounds for treating cancer
|
AU2018230737B2
(en)
|
2017-03-08 |
2022-09-22 |
Takeda Pharmaceutical Company Limited |
Tyk2 inhibitors, uses, and methods for production thereof
|
CN110418796A
(zh)
|
2017-03-08 |
2019-11-05 |
施万生物制药研发Ip有限责任公司 |
托法替尼(tofacitinib)的葡萄糖苷酸前药
|
EP3375784A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aza-dihydro-acridone derivatives
|
EP3375778A1
(en)
|
2017-03-14 |
2018-09-19 |
Artax Biopharma Inc. |
Aryl-piperidine derivatives
|
WO2018191146A1
(en)
|
2017-04-10 |
2018-10-18 |
Navitor Pharmaceuticals, Inc. |
Heteroaryl rheb inhibitors and uses thereof
|
WO2018197893A1
(en)
|
2017-04-27 |
2018-11-01 |
Bicycletx Limited |
Bicyclic peptide ligands and uses thereof
|
BR112019024322A2
(pt)
|
2017-05-22 |
2020-06-16 |
F. Hoffmann-La Roche Ag |
Compostos e composições terapêuticos e métodos de uso dos mesmos
|
EP3609903A1
(en)
|
2017-05-23 |
2020-02-19 |
Theravance Biopharma R&D IP, LLC |
Thiocarbamate prodrugs of tofacitinib
|
AU2018273866B2
(en)
|
2017-05-23 |
2021-09-30 |
Theravance Biopharma R&D Ip, Llc |
Glucuronide prodrugs of Janus kinase inhibitors
|
JP7301757B2
(ja)
|
2017-06-26 |
2023-07-03 |
バイスクルアールディー・リミテッド |
検出可能部分を持つ二環式ペプチドリガンドおよびその使用
|
CN117946114A
(zh)
|
2017-07-28 |
2024-04-30 |
武田药品工业株式会社 |
Tyk2抑制剂与其用途
|
US20200283482A1
(en)
|
2017-08-14 |
2020-09-10 |
Bicyclerd Limited |
Bicyclic peptide ligand prr-a conjugates and uses thereof
|
US10759865B2
(en)
|
2017-08-22 |
2020-09-01 |
Eyal Levit |
Treatment of diabetes mellitus
|
US11883497B2
(en)
|
2017-08-29 |
2024-01-30 |
Puretech Lyt, Inc. |
Lymphatic system-directing lipid prodrugs
|
AU2018324037A1
(en)
|
2017-08-29 |
2020-04-16 |
Monash University |
Lymphatic system-directing lipid prodrugs
|
EP3684366A4
(en)
|
2017-09-22 |
2021-09-08 |
Kymera Therapeutics, Inc. |
CRBN LIGANDS AND USES OF THE LATEST
|
IL273432B
(en)
|
2017-09-22 |
2022-09-01 |
Kymera Therapeutics Inc |
Protein compounds and their uses
|
CN107793418B
(zh)
*
|
2017-10-24 |
2020-08-04 |
扬子江药业集团有限公司 |
一种枸橼酸托法替布的工业化生产方法
|
US10596161B2
(en)
|
2017-12-08 |
2020-03-24 |
Incyte Corporation |
Low dose combination therapy for treatment of myeloproliferative neoplasms
|
TWI825046B
(zh)
|
2017-12-19 |
2023-12-11 |
英商拜西可泰克斯有限公司 |
Epha2特用之雙環胜肽配位基
|
US11608345B1
(en)
|
2017-12-19 |
2023-03-21 |
Puretech Lyt, Inc. |
Lipid prodrugs of rapamycin and its analogs and uses thereof
|
US11304954B2
(en)
|
2017-12-19 |
2022-04-19 |
Puretech Lyt, Inc. |
Lipid prodrugs of mycophenolic acid and uses thereof
|
GB201721265D0
(en)
|
2017-12-19 |
2018-01-31 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for EphA2
|
SG11202005912PA
(en)
|
2017-12-26 |
2020-07-29 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
US11485743B2
(en)
|
2018-01-12 |
2022-11-01 |
Kymera Therapeutics, Inc. |
Protein degraders and uses thereof
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
CN111867581B
(zh)
|
2018-01-29 |
2023-12-26 |
默克专利股份有限公司 |
Gcn2抑制剂及其用途
|
TWI816742B
(zh)
|
2018-01-29 |
2023-10-01 |
美商維泰克斯製藥公司 |
Gcn2抑制劑及其用途
|
WO2019152374A1
(en)
|
2018-01-30 |
2019-08-08 |
Incyte Corporation |
Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
|
EA202091742A1
(ru)
|
2018-02-27 |
2021-02-19 |
Артакс Биофарма Инк. |
ПРОИЗВОДНЫЕ ХРОМЕНА В КАЧЕСТВЕ ИНГИБИТОРОВ ВЗАИМОДЕЙСТВИЯ TCR-Nck
|
MX2020010322A
(es)
|
2018-03-30 |
2022-11-30 |
Incyte Corp |
Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de actividad de la cinasa janus (jak).
|
SI3784666T1
(sl)
|
2018-04-24 |
2022-07-29 |
Merck Patent Gmbh |
Antiproliferacijske spojine in njihove uporabe
|
EP3787664B1
(en)
|
2018-05-03 |
2024-02-28 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Peptide hydrogels for delivery of immunosuppressive drugs and uses thereof
|
EA202092829A1
(ru)
|
2018-05-24 |
2021-05-20 |
Синтон Б.В. |
Композиции тофацитиниба с контролируемым высвобождением
|
CN112423843B
(zh)
|
2018-06-15 |
2023-11-28 |
詹森药业有限公司 |
雷帕霉素类似物和其用途
|
US11180531B2
(en)
|
2018-06-22 |
2021-11-23 |
Bicycletx Limited |
Bicyclic peptide ligands specific for Nectin-4
|
GB201810316D0
(en)
|
2018-06-22 |
2018-08-08 |
Bicyclerd Ltd |
Peptide ligands for binding to EphA2
|
WO2020010177A1
(en)
|
2018-07-06 |
2020-01-09 |
Kymera Therapeutics, Inc. |
Tricyclic crbn ligands and uses thereof
|
CN108822112B
(zh)
*
|
2018-08-13 |
2019-12-20 |
山东罗欣药业集团恒欣药业有限公司 |
一种托法替尼化合物的制备方法
|
EP3866789A4
(en)
|
2018-10-15 |
2022-07-06 |
Nimbus Lakshmi, Inc. |
TYK2 INHIBITORS AND USES THEREOF
|
EP3870597A1
(en)
|
2018-10-23 |
2021-09-01 |
BicycleTx Limited |
Bicyclic peptide ligands and uses thereof
|
WO2020112937A1
(en)
|
2018-11-30 |
2020-06-04 |
Nimbus Lakshmi, Inc. |
Tyk2 inhibitors and uses thereof
|
US11352350B2
(en)
|
2018-11-30 |
2022-06-07 |
Kymera Therapeutics, Inc. |
IRAK degraders and uses thereof
|
EP3903828A4
(en)
|
2018-12-21 |
2022-10-05 |
Daiichi Sankyo Company, Limited |
COMBINATION OF AN ANTIBODY-DRUG CONJUGATE AND A KINASE INHIBITOR
|
KR102131107B1
(ko)
|
2019-01-15 |
2020-07-07 |
주식회사 다산제약 |
3-아미노-피페리딘 화합물의 신규한 제조 방법
|
JP2022518505A
(ja)
|
2019-01-23 |
2022-03-15 |
ニンバス ラクシュミ, インコーポレイテッド |
Tyk2阻害剤およびその使用
|
US20220153743A1
(en)
|
2019-03-13 |
2022-05-19 |
Intas Pharmaceuticals Ltd. |
Process for preparation of tofacitinib and pharmaceutically acceptable salt thereof
|
WO2020198583A1
(en)
|
2019-03-27 |
2020-10-01 |
Insilico Medicine Ip Limited |
Bicyclic jak inhibitors and uses thereof
|
AU2020253990A1
(en)
|
2019-04-02 |
2021-10-28 |
Bicycletx Limited |
Bicycle toxin conjugates and uses thereof
|
MA55565A
(fr)
|
2019-04-05 |
2022-02-09 |
Kymera Therapeutics Inc |
Agents de dégradation de stat et leurs utilisations
|
BR112021022682A2
(pt)
|
2019-05-14 |
2022-02-22 |
Provention Bio Inc |
Métodos e composições para prevenir diabetes do tipo 1
|
CN114502540A
(zh)
|
2019-05-31 |
2022-05-13 |
医肯纳肿瘤学公司 |
Tead抑制剂和其用途
|
WO2020244614A1
(zh)
*
|
2019-06-05 |
2020-12-10 |
南京明德新药研发有限公司 |
吡咯并嘧啶类化合物及其应用
|
TW202118770A
(zh)
|
2019-07-30 |
2021-05-16 |
英商拜西可泰克斯有限公司 |
異質雙環肽複合物
|
EP4021451A1
(en)
|
2019-08-29 |
2022-07-06 |
Synthon B.V. |
Controlled release tofacitinib compositions
|
EP4028385A4
(en)
|
2019-09-11 |
2023-11-08 |
Vincere Biosciences, Inc. |
USP30 INHIBITORS AND USES THEREOF
|
MX2022002877A
(es)
|
2019-09-13 |
2022-08-08 |
Nimbus Saturn Inc |
Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
|
AU2020385054B2
(en)
|
2019-11-14 |
2023-10-12 |
Pfizer Inc. |
1-(((2S,3S,4S)-3-ethyl-4-fluoro-5-oxopyrrolidin-2-yl)methoxy)-7-methoxyisoquinoline-6-carboxamide combinations and oral dosage forms
|
EP4061367A1
(en)
*
|
2019-11-22 |
2022-09-28 |
Incyte Corporation |
Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor
|
CA3163680A1
(en)
|
2019-12-05 |
2021-06-10 |
David John O'neill |
Rapamycin analogs and uses thereof
|
BR112022011651A2
(pt)
|
2019-12-17 |
2022-08-23 |
Kymera Therapeutics Inc |
Degradadores de irak e usos dos mesmos
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADERS AND USES THEREOF
|
TW202136242A
(zh)
|
2019-12-23 |
2021-10-01 |
美商凱麥拉醫療公司 |
Smarca降解劑及其用途
|
US20210268115A1
(en)
|
2020-02-05 |
2021-09-02 |
Puretech Lyt, Inc. |
Lipid prodrugs of neurosteroids
|
AU2021230289A1
(en)
|
2020-03-03 |
2022-09-29 |
PIC Therapeutics, Inc. |
eIF4E inhibitors and uses thereof
|
JP2023518423A
(ja)
|
2020-03-19 |
2023-05-01 |
カイメラ セラピューティクス, インコーポレイテッド |
Mdm2分解剤およびそれらの使用
|
WO2021198980A1
(en)
|
2020-04-04 |
2021-10-07 |
Pfizer Inc. |
Methods of treating coronavirus disease 2019
|
US11766438B2
(en)
|
2020-04-24 |
2023-09-26 |
Slayback Pharma Llc |
Pharmaceutical compositions of tofacitinib for oral administration
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
EP3944859A1
(en)
|
2020-07-30 |
2022-02-02 |
Assistance Publique Hôpitaux de Paris |
Method for treating immune toxicities induced by immune checkpoint inhibitors
|
EP4230214A1
(en)
|
2020-10-30 |
2023-08-23 |
D-Nature Co., Ltd. |
Composition for preventing and treating anti-inflammatory and autoimmune diseases and non-alcoholic fatty liver disease, comprising extract derived from centipeda minima
|
IL303376A
(en)
|
2020-12-02 |
2023-08-01 |
Ikena Oncology Inc |
TEAD inhibitors and their uses
|
AU2022216810A1
(en)
|
2021-02-02 |
2023-08-24 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
KR20230145446A
(ko)
|
2021-02-15 |
2023-10-17 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Irak4 분해제 및 이의 용도
|
CN117295737A
(zh)
|
2021-03-05 |
2023-12-26 |
林伯士萨顿公司 |
Hpk1拮抗剂和其用途
|
EP4323066A1
(en)
|
2021-04-16 |
2024-02-21 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
EP4347028A1
(en)
|
2021-06-04 |
2024-04-10 |
Synthon B.V. |
Prolonged release tofacitinib compositions
|
WO2023028235A1
(en)
|
2021-08-25 |
2023-03-02 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
US20230134932A1
(en)
|
2021-08-25 |
2023-05-04 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
EP4180042A1
(en)
|
2021-11-15 |
2023-05-17 |
Sanovel Ilac Sanayi Ve Ticaret A.S. |
A film coated tablet comprising micronized tofacitinib
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2024042218A1
(en)
|
2022-08-26 |
2024-02-29 |
Synthon B.V. |
Prolonged release tofacitinib compositions without functional coating
|